Nature Communications (Nov 2021)
CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease
- Emmanouela Tsagkaraki,
- Sarah M. Nicoloro,
- Tiffany DeSouza,
- Javier Solivan-Rivera,
- Anand Desai,
- Lawrence M. Lifshitz,
- Yuefei Shen,
- Mark Kelly,
- Adilson Guilherme,
- Felipe Henriques,
- Nadia Amrani,
- Raed Ibraheim,
- Tomas C. Rodriguez,
- Kevin Luk,
- Stacy Maitland,
- Randall H. Friedline,
- Lauren Tauer,
- Xiaodi Hu,
- Jason K. Kim,
- Scot A. Wolfe,
- Erik J. Sontheimer,
- Silvia Corvera,
- Michael P. Czech
Affiliations
- Emmanouela Tsagkaraki
- Program in Molecular Medicine, University of Massachusetts Medical School
- Sarah M. Nicoloro
- Program in Molecular Medicine, University of Massachusetts Medical School
- Tiffany DeSouza
- Program in Molecular Medicine, University of Massachusetts Medical School
- Javier Solivan-Rivera
- Program in Molecular Medicine, University of Massachusetts Medical School
- Anand Desai
- Program in Molecular Medicine, University of Massachusetts Medical School
- Lawrence M. Lifshitz
- Program in Molecular Medicine, University of Massachusetts Medical School
- Yuefei Shen
- Program in Molecular Medicine, University of Massachusetts Medical School
- Mark Kelly
- Program in Molecular Medicine, University of Massachusetts Medical School
- Adilson Guilherme
- Program in Molecular Medicine, University of Massachusetts Medical School
- Felipe Henriques
- Program in Molecular Medicine, University of Massachusetts Medical School
- Nadia Amrani
- University of Crete School of Medicine
- Raed Ibraheim
- RNA Therapeutics Institute, University of Massachusetts Medical School
- Tomas C. Rodriguez
- RNA Therapeutics Institute, University of Massachusetts Medical School
- Kevin Luk
- Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School
- Stacy Maitland
- Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School
- Randall H. Friedline
- Program in Molecular Medicine, University of Massachusetts Medical School
- Lauren Tauer
- Program in Molecular Medicine, University of Massachusetts Medical School
- Xiaodi Hu
- Program in Molecular Medicine, University of Massachusetts Medical School
- Jason K. Kim
- Program in Molecular Medicine, University of Massachusetts Medical School
- Scot A. Wolfe
- Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School
- Erik J. Sontheimer
- Program in Molecular Medicine, University of Massachusetts Medical School
- Silvia Corvera
- Program in Molecular Medicine, University of Massachusetts Medical School
- Michael P. Czech
- Program in Molecular Medicine, University of Massachusetts Medical School
- DOI
- https://doi.org/10.1038/s41467-021-27190-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
Worldwide pandemics of obesity and diabetes prompt an urgent need for new approaches to their prevention and cure. Here the authors present a CRISPR-based strategy that enhances the therapeutic potential of human adipocytes when implanted in obese mice.
